P/B
—
ProKidney
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
$346.8M
Market Cap • 10/8/2026
2021
(5 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
424
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
346,8M
EV
1,3B
EV/Revenue
1558,9
EV/EBITDA
-7,5
EV/EBIT
-7,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-7,6%
Total Yield
-7,6%
Payout
0%
Retained Earnings
-1,3B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
16004,3%
Capex/Revenue
2269,8%
Capex/D&A
271,2%
Capex/OCF
-13,2%
SBC/OCF
—
% PPE
23,8%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1
Debt/Equity
0%
Current Ratio
8,4
Quick Ratio
8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!